| TIDM | Instrument | Type | Currency | Venue |
|---|---|---|---|---|
| ANAB | ANAB | Shares | USD | XNGS |
| TIDM | Instrument | Type | Currency | Venue |
|---|---|---|---|---|
| ANAB | ANAB | Shares | USD | XNGS |
AnaptysBio, Inc. is a biotechnology company based in San Diego, California, focused on managing financial collaborations related to its royalty assets. The company primarily oversees royalties from two therapeutic products: Jemperli in collaboration with GSK and imsidolimab with Vanda. AnaptysBio aims to protect and maximize the value of these royalties for its shareholders while also engaging in the development of monoclonal antibodies for autoimmune diseases, including a clinical trial for ANB033 targeting celiac disease.
No recent RNS announcements for ANAB across ANAB.
No recent RNS announcements for ANAB across ANAB.